Annie Killoran, MD, MS

Clinical Assistant Professor of Neurology


MS, Pathology and Molecular Medicine, Queen’s University
MD, Medicine, University College Dublin, National University of Ireland
Resident, Neurology, Michigan State University
Fellow, Movement Disorders - Experimental Therapeutics, University of Rochester Medical Center


Killoran, A. (2017). The Clinical Features of Huntington's Disease. In C. Hughes (Eds.) Huntington's Disease: Prevalence, Pathogenesis and Treatment. Nova Science Publishers.

Killoran, A., Biglan, K. (2016). Biomarkers for Huntington’s disease: a brief overview. Journal of Rare Disease Research & Treatment., 1(2), 46-50.

Killoran, A., Biglan, K. M. (2014). Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches?. Movement disorders : official journal of the Movement Disorder Society, 29(11), 1404-13. PMID: 25164707.

Killoran, A., Biglan, K. M. (2014). Movement, Facial. In D. Weisbrot , A. Ettinger (Eds.) Neurological Differential Diagnosis: A Case-based Approach. pp. 247-249. Cambridge University Press. PMID: 1107014557.

Killoran, A., Biglan, K. M., Jankovic, J., Eberly, S., Kayson, E., Oakes, D., Young, A. B. & Shoulson, I. (2013). Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology, 80(22), 2022-7. PMID: 23624566.

Abdolahi, A., Scoglio, N., Killoran, A., Dorsey, E. R. & Biglan, K. M. (2013). Potential reliability and validity of a modified version of the Unified Parkinson's Disease Rating Scale that could be administered remotely. Parkinsonism & related disorders, 19(2), 218-21. PMID: 23102808.

Biglan, K. M., Zhang, Y., Long, J. D., Geschwind, M., Kang, G. A., Killoran, A., Lu, W., McCusker, E., Mills, J. A., Raymond, L. A., Testa, C., Wojcieszek, J. & Paulsen, J. S. (2013). Refining the diagnosis of Huntington disease: the PREDICT-HD study. Frontiers in aging neuroscience, 5, 12. PMID: 23565093.

Killoran, A., Biglan, K. M. (2012). 8-OHdG: its (limited) potential as a biomarker for Huntington's disease. (Vols. 6). (6), pp. 777-80. Biomarkers in medicine. PMID: 23227841.

Killoran, A. (2012). Ask the Experts. Neurology Now, 8(2), 35. DOI: 10.1097/01.nnn.0000414219.75201.0b.

Killoran, A., Biglan, K. M. (2012). Therapeutics in Huntington's Disease. Current treatment options in neurology. PMID: 22314929.

Killoran, A., Marshall, F. (In Press). Parkinsonian Syndromes: Co 1 tricobasal degeneration. In S. Gilman , J. Markovac (Eds.) Neurobiology of disease. (2nd ed.) Oxford University Press.

Thompson, M. D., Killoran, A., Percy, M. E., Nezarati, M., Cole, D. E. & Hwang, P. A. (2006). Hyperphosphatasia with neurologic deficit: a pyridoxine-responsive seizure disorder?. Pediatric neurology, 34(4), 303-7. PMID: 16638507.

Bouwman, C. W., Kohli, M., Killoran, A., Touchie, G. A., Kadner, R. J. & Martin, N. L. (2003). Characterization of SrgA, a Salmonella enterica serovar Typhimurium virulence plasmid-encoded paralogue of the disulfide oxidoreductase DsbA, essential for biogenesis of plasmid-encoded fimbriae. Journal of bacteriology, 185(3), 991-1000. PMID: 12533475.

Notley, C., Killoran, A., Cameron, C., Wynd, K., Hough, C. & Lillicrap, D. (2002). The canine factor VIII 3'-untranslated region and a concatemeric hepatocyte nuclear factor 1 regulatory element enhance factor VIII transgene expression in vivo. Human gene therapy, 13(13), 1583-93. PMID: 12228013.